Volume 3.47 | Dec 7

Prostate Cell News 3.47 December 7, 2012
     In this issue: Publications | Reviews | Industry News | Policy News | Events | Jobs
Cell Therapy News on Facebook  Prostate Cell News on Twitter
Novel Oncogene Induced Metastatic Prostate Cancer Cell Lines Define Human Prostate Cancer Progression Signatures
Murine prostate cancer cell lines, generated via selective transduction with a single oncogene (c-Myc, Ha-Ras, and v-Src), demonstrated oncogene-specific prostate cancer molecular signatures that were recapitulated in human prostate cancer, and developed lung metastasis in immune competent mice. [Cancer Res] Abstract

[Free Webinar] ALDH+ Cancer Precursor Cells in Drug Response Prediction - Watch Now.
PUBLICATIONS (Ranked by impact factor of the journal)


Metabolic Intervention on Lipid Synthesis Converging Pathways Abrogates Prostate Cancer Growth
One of the most conserved features of all cancers is a profound reprogramming of cellular metabolism, favoring biosynthetic processes and limiting catalytic processes. With the acquired knowledge of some of these important changes, researchers have designed a combination therapy in order to force cancer cells to use a particular metabolic pathway that ultimately results in the accumulation of toxic products. [Oncogene] Full Article

A Novel Semisynthetic Inhibitor of the FRB Domain of Mammalian Target of Rapamycin Blocks Proliferation and Triggers Apoptosis in Chemoresistant Prostate Cancer Cells
The authors synthesized and chemically characterized a novel, semisynthetic triterpenoid derivative, 3-cinnamoyl-11-keto-β-boswellic acid. Its pharmacodynamic effects on mammalian target of rapamycin and several other signaling pathways were assessed in a number of prostate and breast cancer cell lines as well as in normal prostate epithelial cells. [Mol Pharmacol] Abstract

Cathepsin H Mediates the Processing of Talin and Regulates Migration of Prostate Cancer Cells
Researchers report that the attenuation of cathepsin H aminopeptidase activity by specific inhibitor or siRNA-mediated silencing significantly reduced the migration of metastatic PC-3 prostate cells on fibronectin, as well as the invasion through Matrigel. [J Biol Chem] Abstract

Prostaglandin 15d-PGJ2 Inhibits Androgen Receptor Signaling in Prostate Cancer Cells
Investigators showed that 15-deoxy-Δ12,14-prostaglandin J2 (15d-PGJ2), an endogenously produced antiinflammatory prostaglandin, targets the androgen receptor (AR) and acts as a potent AR inhibitor, rapidly repressing AR target genes, such as FKBP51 and TMPRSS2 in prostate cancer cells. [Mol Endocrinol] Abstract

ARHGAP21 Is a RhoGAP for RhoA and RhoC with a Role in Proliferation and Migration of Prostate Adenocarcinoma Cells
ARHGAP21 is a Rho GTPase-activating proteins (RhoGAP) with increased expression in head and neck squamous cell carcinoma and with a possible role in glioblastoma tumor progression, yet little is known about the function of ARHGAP21 in cancer cells. Scientists studied the role of ARHGAP21 in two prostate adenocarcinoma cell lines, LNCaP and PC3, which respectively represent initial and advanced stages of prostate carcinogenesis. [Biochim Biophys Acta] Abstract

Modeling Truncated AR Expression in a Natural Androgen Responsive Environment and Identification of RHOB as a Direct Transcriptional Target
Researchers present a model system in which a C-terminally truncated variant of androgen receptor (TC-AR) is inducibly expressed in LNCaP, an androgen-dependent cell line, which expresses little truncated receptor. They observed that when TC-AR is overexpressed, the endogenous full length receptor is transcriptionally downmodulated. [PLoS One] Full Article

Purple Corn Color Inhibition of Prostate Carcinogenesis by Targeting Cell Growth Pathways
Purple corn color is a widely used food colorant that was reported to have attenuating effects on hypertension, diabetes, and to have anti-cancer effects on colon and breast cancer. This is the first study on its possible chemoprevention effects against prostate cancer. For this purpose an androgen-dependent prostate cancer cell line, LNCaP, was used to examine effects in vitro. [Cancer Sci] Abstract

Acquisition of Paclitaxel Resistance Is Associated with a More Aggressive and Invasive Phenotype in Prostate Cancer
The authors established paclitaxel resistance in a classic, androgen-insensitive mCRPC cell line and, using a suite of molecular and biophysical methods, characterized the structural and functional changes in vitro and in vivo that are associated with the development of drug resistance. [J Cell Biochem] Abstract


Cellular Immunotherapy Study of Prostate Cancer Patients and Resulting IgG Responses to Peptide Epitopes Predicted from Prostate Tumor-Associated Autoantigens
In this dose escalation Phase I study, researchers report safety, feasibility, and immunologic data of an immunotherapy composed of two human prostate cancer cell lines engineered to express α1,3galactosyl epitopes. [J Immunother] Abstract

Multicenter Experience with Robot-Assisted Radical Prostatectomy in Renal Transplant Recipients
Researchers aimed to evaluate their multi-institutional outcome with robot-assisted radical prostatectomy in renal transplant recipients and describe technical modifications of the procedure. [Urology] Abstract

FREE ALDEFLUOR™ Protocol Optimization Resource Pack – Get Yours

Sequencing the Transcriptional Network of Androgen Receptor in Prostate Cancer
The authors highlight some of the novel and unexpected mechanistic and functional insights of the androgen receptor (AR) transcriptional network derived from recent targeted sequencing studies of AR and its coregulatory factors in prostate cancer cells. [Cancer Lett] Abstract

Parabon NanoLabs Awarded NSF Grant for Development of Cancer Therapeutic with Industry Partner Janssen R&D
Parabon NanoLabs, Inc. announced that it has received a joint grant award from the National Science Foundation (NSF) for a project with Janssen Research & Development, LLC. The funds will support development and testing of a novel therapeutic for prostate cancer – the most common cause of death from cancer in men over age 75. [Parabon NanoLabs Inc.] Press Release

Clinical Trial at GHSU Cancer Center Targets Advanced Prostate Cancer
Select patients with advanced prostate cancer may benefit from a Georgia Health Sciences University (GSHU) Cancer Center clinical trial that looks to improve survival rates of the FDA-approved prostate cancer drug Provenge. [Georgia Health Sciences University] Press Release


National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)


NEW American Association for Cancer Research Annual Meeting 2013
April 6-10, 2013
Washington, United States

our events page to see a complete list of events in the prostate cell community.


Product Quality Scientist (STEMCELL Technologies, Inc.)

Scientist – Endothelial Cell Research (STEMCELL Technologies, Inc.)

Research Technologist – Cell Separation (STEMCELL Technologies, Inc.)

Scientist or Engineer – hPSC Bioengineer (STEMCELL Technologies, Inc)

Quality Control Analyst (STEMCELL Technologies, Inc.)

Postdoctoral Position – Biomarkers in Prostate Cancer (Roswell Park Cancer Institute, Buffalo)

Postdoctoral Position – Tumor Stem Cells (Cancer Institute of New Jersey)

PhD Studentship – Investigation into Chemokine Receptor Induced Cell Migration (University of East Anglia)

Postdoctoral Position – Translational Program in Endocrine-Related Cancers (Baylor College of Medicine)

PhD Student – Multi-Compartment Magnetic Resonance Imaging of Prostate Cancer (University of East Anglia)

Recruit Top Talent : Reach more than 55,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Prostate Cell News? Click here to submit!

Comments or Suggestions? Email [email protected] with your feedback.

Learn more about Prostate Cell News: Archives | Events | Contact Us